Scripsamerica Inc · OTC:SCRCQ
Scripsamerica — Investor Presentation (April 2015)
25 slides from Scripsamerica's investor presentation, April 2015
Slide 1: Spring 2015
Spring 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not s
Slide 3: ScripsAmerica, Inc.
ScripsAmerica, Inc. A leading, vertically integrated provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies Serving large and growing markets: Specialty Pharmaceuticals & Medical Supplies Rapid Growth, Improving Financial Performance, Projecting Q
Slide 4: Trading Snapshot
Trading Snapshot Symbol SCRC Exchange OTCBB Price (4/1/15) $0.12 Market Capitalization (4/1/15) ~ $17 MM 52- Week Range $0.08 - $0.22 Average Daily Volume 500,000 Shares Outstanding/Authorized 139MM/250MM Corporate Headquarters Tysons Corner, Virginia
Slide 5: Share Structure
Share Structure 138,829,119Outstanding 37,000,000Held By Founders 17,000,000Restricted 40,000,000Held By Core Group
Slide 6: ScripsAmerica: Evolution of A Healthcare Leader
ScripsAmerica: Evolution of A Healthcare Leader 2010 Operations Commence 2010 – 2012 Pharmaceutical distribution services (primarily McKesson) Retail, hospitals, long-term care facilities and government and home care agencies 2013 McKesson squeezes margins, increases chargebacks 2013-2014
Slide 7: One Platform – Multiple Opportunities
One Platform – Multiple Opportunities ScripsAmerica Established Operations Evolving Operations Main Avenue PIMD Wholesale Rx Evolving Businesses Pharmacy Q1 2015 2014 Revenues Revenues @$29,000,000.00 @$912,000.00 Physician Diabetic RapiMed Dispensing Supplies $200,000 Order 750+ Pending Patients Si
Slide 8: The Specialty Pharmaceuticals Market
The Specialty Pharmaceuticals Market Estimated 1% - 5% of population cannot tolerate medications in standard formulas* Specialty pharmacy industry growth drivers: Shortages of mass-produced drugs Increased awareness of compounding pharmacies and pharmaceutical applications Physicians concerned
Slide 9: ScripsAmerica’s Specialty Pharma Business
ScripsAmerica’s Specialty Pharma Business Main Avenue Pharmacy acquired Feb. 14, 2014 (100% effective October 2014) Offering a wide variety of specialty pharmaceutical products to treat pain, scars, wounds, vitamin deficiencies among others FDA approved and licensed in 10 states Additional s
Slide 10: Pre-Approval Avoids Collection Risk
Pre-Approval Avoids Collection Risk Doctor writes prescription and sends to Pharmacy Submitted for payment to Insurance Company/Third party payers No Medicaid, Medicare 200 6 Prescription approved for payment, charge set by PBM Order to compound transmitted to Main Avenue Pharmacy Bill gen
Slide 11: Case Study: Just One of ScripsAmerica’s Many Products
Case Study: Just One of ScripsAmerica’s Many Products More than 100 million Americans suffer from chronic pain 83% reported significant reduction in their pain after using custom-compounded prescription pain creams On average, survey respondents said the creams reduced their pain levels by more
Slide 12: Specialty Pharmaceuticals Growth Strategy
Specialty Pharmaceuticals Growth Strategy Expand Licensing to New States Add Pharmacies with states not currently serving Bring on Additional Marketing Partners Introduce New Products
Slide 13: Other Growth Platforms
Other Growth Platforms RapiMed – Child Pain & Fever Relief tablets- Approval Pending PIMD International Physician Dispensing Program Diabetic Medical Supplies
Slide 14: RapiMed Oral Delivery Technology
RapiMed Oral Delivery Technology Rapid Release, Fast Dissolving Fever & Pain Relief Tablets Over The Counter Product Manufactured in United States Regulated dosage (80mg, 160mg) for children 2 – 11 Signed Contract with Distributor in China $200,000 order pending- $60,000 Cost (Attractive M
Slide 15: PIMD International, LLC
PIMD International, LLC Problem: Small chains/individual pharmacies unable to fill prescriptions for controlled substances Product manufacturers impose minimum order quantities far beyond the needs of the smaller operations Solution: A DEA and State licensed business that represents independen
Slide 16: Physician Dispensing Program
Physician Dispensing Program Doctor Credentialed by service PIMD Supplies Inventory based on practice history Dr writes Rx Office bills PBM Dr dispenses Rx Patient receives Rx without having to go to pharmacy to pick up medication 3 out of 4 patients prefer to receive their medications
Slide 17: Strong, Experienced Leadership Team
Strong, Experienced Leadership Team Robert Schneiderman, CEO & Founder Accomplished entrepreneur with proven track record building businesses and creating value for shareholders CEO of one of Philadelphia’s leading recruitment firms for 32 years Jeffrey Andrews, CFO Finance professional with e
Slide 18: Financial Results
Financial Results >
Slide 19: Recent Results of Operations
Recent Results of Operations Significant Improvement In millions, except EPS 2014 (P) 2013 Improvement Net Revenues $ 30.0 $ 0.60 + $ 29.4 Operating Income ($ 0.01) ($ 7.4) + $ 7.4 Net (Loss) ($ 1.2) $(11.3) + $ 10.1 EPS ($ 0.01) ($ 0.17) + $ 0.16 Shares 127.5 68.1 (P) Preliminary results, subject t
Slide 20: First Quarter 2015 Profitable
First Quarter 2015 Profitable March 31, March 31, 2015 2014 (Projected) (Actual) (3 months) (3 months) Revenue $ 9,600,000 $ 800,000 Operating Income* $ 1,001,000 $ 612 Income (loss) from Operations $ 594,000 ($ 214,000) Net Income (loss)** $ 407,000 ($1,213,000) * prior to shares issued for service
Slide 21: Strong & Improving Financial Position
Strong & Improving Financial Position December 31, 2014* December 31, 2013 * (000’s omitted) Cash $ 730 $ 47 Receivables $ 2,679 $ 1,089 Inventory $ 1,011 $ -0- Total Current Assets $ 4,699 $ 1,490 Total Assets $ 5,659 $ 1,781 Line of Credit $ 653 $ 99 Payables & Accruals $ 2,268 $ 227 Purchase Orde
Slide 22: Capital Structure
Capital Structure 12/31/14 12/31/13 Working Capital $1.350 MM ($1.698 MM) 149 Shareholders of record Preferred Convertible Debt - $1MM-Held by Board Member, Convertible into 6MM shares @ $.175 Term Debt – $233,000, 9% due 9/2016. Holder: Board member Convertible Debt: $616,000 convertible
Slide 23: ScripsAmerica – Summary
ScripsAmerica — Summary >
Slide 24: ScripsAmerica – Strategy
ScripsAmerica – Strategy Expand the Compounding Rx Business -Add new Pharmacies, Products and Formulations Launch RapiMeds Launch Physician Dispensing Program Add New Formulations of the Oral Delivery Technology Strategic Acquisitions Eliminate Convertible Notes/Pay Off Unsecured Debt
Slide 25: Contact Information
CONTACT INFORMATION www.scripsamerica.com Robert Schneiderman, CEO 800-957-7622 ext 101 bob@scripsamerica.com Jeffrey J. Andrews, CFO 800-957-7622 ext 102 Jeff@scripsamerica.com